Our results also highlight the importance of the EGFR-Ras-FOXM1-β-catenin signaling axis in CRC and indicate that the expression of the transcription factor FOXM1 in colorectal tumors may be a potential predictive marker of response to cetuximab therapy in this disease. The gene discussed is FOXM1; the disease is colorectal neoplasm.